
Quarterly report 2024-Q4
added 05-06-2026
Trinity Biotech plc Revenue 2011-2026 | TRIB
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Trinity Biotech plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61.6 M | 56.8 M | 62.5 M | 81.1 M | 102 M | 90.4 M | 97 M | 99.1 M | 99.6 M | 100 M | 105 M | 91.2 M | 82.5 M | 77.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 105 M | 56.8 M | 86.2 M |
Quarterly Revenue Trinity Biotech plc
| 2024-Q4 | 2024-Q2 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61.6 M | 30.5 M | 56.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25 M | - | - | - | 25.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 61.6 M | 25 M | 39.9 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Co-Diagnostics
CODX
|
622 K | $ 1.29 | -20.63 % | $ 1.72 M | ||
|
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M | ||
|
Fulgent Genetics
FLGT
|
283 M | $ 15.93 | -1.61 % | $ 482 M | ||
|
Agilent Technologies
A
|
6.32 B | $ 112.11 | -1.0 % | $ 34.1 B | ||
|
Castle Biosciences
CSTL
|
344 M | $ 19.08 | 1.06 % | $ 553 M | ||
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
343 K | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | ||
|
Illumina
ILMN
|
4.37 B | $ 140.65 | -1.81 % | $ 22.4 B | ||
|
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M | ||
|
Interpace Biosciences
IDXG
|
38.7 M | $ 1.8 | - | $ 7.96 M | ||
|
CareDx, Inc
CDNA
|
380 M | $ 19.81 | -3.32 % | $ 1.06 B | ||
|
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | ||
|
Lantheus Holdings
LNTH
|
1.54 B | $ 93.98 | -2.78 % | $ 6.34 B | ||
|
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | ||
|
Medpace Holdings
MEDP
|
2.53 B | $ 419.51 | 0.08 % | $ 12.1 B | ||
|
Mettler-Toledo International
MTD
|
4.03 B | $ 1 046.9 | 0.48 % | $ 21.6 B | ||
|
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M | ||
|
Myriad Genetics
MYGN
|
824 M | $ 3.61 | -0.28 % | $ 334 M | ||
|
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | ||
|
NeoGenomics
NEO
|
727 M | $ 8.28 | -1.02 % | $ 1.06 B | ||
|
Charles River Laboratories International
CRL
|
4.02 B | $ 155.13 | -2.51 % | $ 7.69 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | ||
|
National Research Corporation
NRC
|
137 M | $ 18.58 | -1.85 % | $ 416 M | ||
|
Natera
NTRA
|
820 M | $ 187.34 | -4.86 % | $ 18.4 B | ||
|
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
3.25 B | - | - | $ 19.8 B | ||
|
Koninklijke Philips N.V.
PHG
|
17.8 B | $ 25.34 | -0.65 % | $ 24 B | ||
|
Guardant Health
GH
|
982 M | $ 93.18 | -5.56 % | $ 11.7 B | ||
|
Senseonics Holdings
SENS
|
35.3 M | $ 5.73 | -1.63 % | $ 239 M | ||
|
Personalis
PSNL
|
69.6 M | $ 6.5 | -3.2 % | $ 580 M | ||
|
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | ||
|
ICON Public Limited Company
ICLR
|
5.48 B | $ 117.79 | 0.6 % | $ 9.72 B | ||
|
Soleno Therapeutics
SLNO
|
190 M | $ 52.99 | - | $ 2.69 B | ||
|
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
5.31 M | $ 2.36 | -2.07 % | $ 5.42 M | ||
|
Laboratory Corporation of America Holdings
LH
|
14 B | $ 252.4 | -0.64 % | $ 21 B | ||
|
Thermo Fisher Scientific
TMO
|
44.6 B | $ 441.45 | -1.49 % | $ 166 B | ||
|
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K | ||
|
Twist Bioscience Corporation
TWST
|
377 M | $ 48.89 | -7.67 % | $ 2.92 B | ||
|
Neogen Corporation
NEOG
|
895 M | $ 8.28 | -1.78 % | $ 1.8 B | ||
|
Waters Corporation
WAT
|
932 M | $ 332.25 | -0.29 % | $ 19.8 B | ||
|
Quest Diagnostics Incorporated
DGX
|
11 B | $ 186.87 | -0.57 % | $ 20.7 B |